Figure 9.

ACE2 is upregulated in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐infected patients. A, Schematic diagrams of the RT‐qPCR primer positions of human ACE2 and glyceraldehyde 3‐phosphate dehydrogenase (GAPDH). The RT‐qPCR primers of ACE2 located in two different exons with a large intron between them to make sure that the primers can only amplify a fragment of ACE2 from complementary DNA (cDNA) only but not genomic DNA. The forward primer of GAPDH (GAPDH‐F) span an exon‐exon boundary as indicated, which only amplify a fragment of GAPDH from cDNA only but not genomic DNA. B, Expression of ACE2 in nasopharyngeal swab specimens from healthy (control, CTR) and SARS‐CoV‐2‐infected individuals. Nasopharyngeal swab specimens collected from patients with COVID‐19 were confirmed to be SARS‐CoV‐2 RNA‐positive. Expression of ACE2 in theses samples was detected by RT‐qPCR. ACE2, angiotensin‐converting enzyme 2; RT‐qPCR, reverse‐transcription quantitative polymerase chain reaction